Results from ACROCOVID: an international survey on the care of acromegaly during the COVID-19 era.
Journal
Endocrine
ISSN: 1559-0100
Titre abrégé: Endocrine
Pays: United States
ID NLM: 9434444
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
19
10
2020
accepted:
22
11
2020
pubmed:
9
1
2021
medline:
24
2
2021
entrez:
8
1
2021
Statut:
ppublish
Résumé
With most global healthcare resources focused on COVID-19, altered resource allocation is disrupting the continuum of care for chronic endocrine conditions, including acromegaly. In order to assess the effects of COVID-19 on care of patients with acromegaly, we conducted an international online survey of endocrinologists. The questionnaire was drafted by a Steering Committee of acromegaly experts and covered both respondent demographics, contact and communication with patients, and patient care. Respondent awareness was generated through social media campaigns and the survey completed online using Google forms. The majority of endocrinologists who responded (N = 84) were based in Europe (67.9%) and were female (58.3%). Slightly more than half of respondents worked in a specialized pituitary center (52.4%) and a large minority cared for more than 50 acromegaly patients (47.6%). Most respondents (85.7%) indicated surgery was their first-line treatment, with only 14.3% indicating medical therapy as a first-choice treatment option. One-third (33.3%) of respondents reported having delayed a planned surgery due to a lack of COVID-19 testing provision and 54.8% due to a lack of surgical provision; 19.1% indicated that a lack of personal protective equipment had reduced their ability to treat patients with acromegaly. Just 21.4% of respondents reported no negative effects from the pandemic on diagnostic practice patterns, and just 19.1% reported no negative effect on patient follow-up practices. Many respondents (55.9%) indicated that remote methods had improved their ability to communicate with their patients and 69.0% indicated that they would continue to use methods of consultation necessitated by the COVID-19 pandemic. Our data suggest the COVID-19 pandemic is substantially affecting the care of acromegaly. However, these results also suggest that endocrinologists are embracing aspects of the 'new normal' to create a novel continuum of care better suited to the presumed post-COVID-19 environment. The goal of these changes must be both to improve care while shielding patients from more severe involvement in concomitant acute illnesses such COVID-19.
Identifiants
pubmed: 33415577
doi: 10.1007/s12020-020-02565-1
pii: 10.1007/s12020-020-02565-1
pmc: PMC7790473
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
273-280Commentaires et corrections
Type : ErratumIn
Références
https://covid19.who.int/ .
https://www.weforum.org/agenda/2020/08/pandemic-fight-costs-500x-more-than-preventing-one-futurity/?emailType=Newsletter .
Y.V. Chudasama, C.L. Gillies, F. Zaccardi, B. Coles, M.J. Davies, S. Seidu, K. Khunti, Impact of COVID-19 on routine care for chronic diseases: a global survey of views from healthcare professionals. Diabetes Metab. Syndr. 14(5), 965–967 (2020). https://doi.org/10.1016/j.dsx.2020.06.042
doi: 10.1016/j.dsx.2020.06.042
pubmed: 32604016
pmcid: 7308780
M. Marazuela, A. Giustina, M. Puig-Domingo, Endocrine and metabolic aspects of the COVID-19 pandemic. Rev. Endocr. Metab. Disord. 21(4), 495–507 (2020). https://doi.org/10.1007/s11154-020-09569-2
doi: 10.1007/s11154-020-09569-2
pubmed: 32643004
M. Puig-Domingo, M. Marazuela, A. Giustina, COVID-19 and endocrine diseases. A statement from the European Society of Endocrinology. Endocrine 68(1), 2–5 (2020). https://doi.org/10.1007/s12020-020-02294-5
doi: 10.1007/s12020-020-02294-5
pubmed: 32279224
J.P. Bilezikian, D. Bikle, M. Hewison, M. Lazaretti-Castro, A.M. Formenti, A. Gupta, M.V. Madhavan, N. Nair, V. Babalyan, N. Hutchings, N. Napoli, D. Accili, N. Binkley, D.W. Landry, A. Giustina, MECHANISMS IN ENDOCRINOLOGY: Vitamin D and COVID-19. Eur. J. Endocrinol. 183(5), R133–R147 (2020). https://doi.org/10.1530/EJE-20-0665
doi: 10.1530/EJE-20-0665
pubmed: 32755992
Middleton, J., Lopes, H., Michelson, K., Reid, J. Planning for a second wave pandemic of COVID-19 and planning for winter: a statement from the Association of Schools of Public Health in the European Region. Int. J. Public Health (2020). https://doi.org/10.1007/s00038-020-01455-7
S. Melmed, Pituitary-tumor endocrinopathies. N. Engl. J. Med. 382(10), 937–950 (2020). https://doi.org/10.1056/NEJMra1810772
doi: 10.1056/NEJMra1810772
pubmed: 32130815
A. Colao, L.F.S. Grasso, A. Giustina, S. Melmed, P. Chanson, A.M. Pereira, R. Pivonello, Acromegaly. Nat. Rev. Dis. Primers 5(1), 20 (2019). https://doi.org/10.1038/s41572-019-0071-6
doi: 10.1038/s41572-019-0071-6
pubmed: 30899019
M.R. Gadelha, L. Kasuki, D.S.T. Lim, M. Fleseriu, Systemic complications of acromegaly and the impact of the current treatment landscape: an update. Endocr. Rev. 40(1), 268–332 (2019). https://doi.org/10.1210/er.2018-00115
doi: 10.1210/er.2018-00115
pubmed: 30184064
D. Esposito, O. Ragnarsson, G. Johannsson, D.S. Olsson, Prolonged diagnostic delay in acromegaly is associated with increased morbidity and mortality. Eur. J. Endocrinol. 182(6), 523–531 (2020). https://doi.org/10.1530/EJE-20-0019
doi: 10.1530/EJE-20-0019
pubmed: 32213651
A. Giustina, Acromegaly: reducing diagnostic delay. Recenti. Prog. Med. 107(8), 450–451 (2016). https://doi.org/10.1701/2332.25074
doi: 10.1701/2332.25074
pubmed: 27571562
A. Giustina, G. Barkhoudarian, A. Beckers, A. Ben-Shlomo, N. Biermasz, B. Biller, C. Boguszewski, M. Bolanowski, J. Bollerslev, V. Bonert, M.D. Bronstein, M. Buchfelder, F. Casanueva, P. Chanson, D. Clemmons, M. Fleseriu, A.M. Formenti, P. Freda, M. Gadelha, E. Geer, M. Gurnell, A.P. Heaney, K.K.Y. Ho, A.G. Ioachimescu, S. Lamberts, E. Laws, M. Losa, P. Maffei, A. Mamelak, M. Mercado, M. Molitch, P. Mortini, A.M. Pereira, S. Petersenn, K. Post, M. Puig-Domingo, R. Salvatori, S.L. Samson, I. Shimon, C. Strasburger, B. Swearingen, P. Trainer, M.L. Vance, J. Wass, M.E. Wierman, K.C.J. Yuen, M.C. Zatelli, S. Melmed, Multidisciplinary management of acromegaly: a consensus. Rev. Endocr. Metab. Disord. 21(4), 667–678 (2020). https://doi.org/10.1007/s11154-020-09588-z
doi: 10.1007/s11154-020-09588-z
pubmed: 32914330
pmcid: 7942783
S. Frara, F. Maffezzoni, G. Mazziotti, A. Giustina, The modern criteria for medical management of acromegaly. Prog. Mol. Biol. Transl. Sci. 138, 63–83 (2016). https://doi.org/10.1016/bs.pmbts.2015.10.015
doi: 10.1016/bs.pmbts.2015.10.015
pubmed: 26940387
M. Fleseriu, M. Buchfelder, J.S. Cetas, P.K. Fazeli, S.M. Mallea-Gil, M. Gurnell, A. McCormack, M.M. Pineyro, L.V. Syro, N.A. Tritos, H.J. Marcus, Pituitary society guidance: pituitary disease management and patient care recommendations during the COVID-19 pandemic-an international perspective. Pituitary 23(4), 327–337 (2020). https://doi.org/10.1007/s11102-020-01059-7
doi: 10.1007/s11102-020-01059-7
pubmed: 32556793
pmcid: 7300368
M. Fleseriu, O.M. Dekkers, N. Karavitaki, Endocrinology in the time of COVID-19: management of pituitary tumours. Eur. J. Endocrinol. 183(1), G17–G23 (2020). https://doi.org/10.1530/EJE-20-0473
doi: 10.1530/EJE-20-0473
pubmed: 32369770
pmcid: 7938006
Giustina, A., Barkan, A., Beckers, A., Biermasz, N., Biller, B. M. K., Boguszewski, C., Bolanowski, M., Bonert, V., Bronstein, M. D., Casanueva, F. F., Clemmons, D., Colao, A., Ferone, D., Fleseriu, M., Frara, S., Gadelha, M. R., Ghigo, E., Gurnell, M., Heaney, A. P., Ho, K., Ioachimescu, A., Katznelson, L., Kelestimur, F., Kopchick, J., Krsek, M., Lamberts, S., Losa, M., Luger, A., Maffei, P., Marazuela, M., Mazziotti, G., Mercado, M., Mortini, P., Neggers, S., Pereira, A. M., Petersenn, S., Puig-Domingo, M., Salvatori, R., Shimon, I., Strasburger, C., Tsagarakis, S., van der Lely, A. J., Wass, J., Zatelli, M. C., Melmed, S. A consensus on the diagnosis and treatment of acromegaly comorbidities: an update. J. Clin. Endocrinol. Metab. 105(4), (2020). https://doi.org/10.1210/clinem/dgz096
S. Melmed, M.D. Bronstein, P. Chanson, A. Klibanski, F.F. Casanueva, J.A.H. Wass, C.J. Strasburger, A. Luger, D.R. Clemmons, A. Giustina, A. Consensus, Statement on acromegaly therapeutic outcomes. Nat. Rev. Endocrinol. 14(9), 552–561 (2018). https://doi.org/10.1038/s41574-018-0058-5
doi: 10.1038/s41574-018-0058-5
pubmed: 30050156
pmcid: 7136157
M. Gola, S. Bonadonna, G. Mazziotti, G. Amato, A. Giustina, Resistance to somatostatin analogs in acromegaly: an evolving concept? J. Endocrinol. Invest. 29(1), 86–93 (2006). https://doi.org/10.1007/BF03349183
doi: 10.1007/BF03349183
pubmed: 16553040
F.F. Casanueva, A.L. Barkan, M. Buchfelder, A. Klibanski, E.R. Laws, J.S. Loeffler, S. Melmed, P. Mortini, J. Wass, A. Giustina, Pituitary Society, Expert Group on Pituitary Tumors, Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): A Pituitary Society Statement. Pituitary 20(5), 489–498 (2017). https://doi.org/10.1007/s11102-017-0838-2
doi: 10.1007/s11102-017-0838-2
pubmed: 28884415
pmcid: 5606938
S. Frara, G. Rodriguez-Carnero, A.M. Formenti, M.A. Martinez-Olmos, A. Giustina, F.F. Casanueva, Pituitary tumors centers of excellence. Endocrinol. Metab. Clin. North Am. 49(3), 553–564 (2020). https://doi.org/10.1016/j.ecl.2020.05.010
doi: 10.1016/j.ecl.2020.05.010
pubmed: 32741488
P. Mortini, G. Nocera, F. Roncelli, M. Losa, A.M. Formenti, A. Giustina, The optimal numerosity of the referral population of pituitary tumors centers of excellence (PTCOE): a surgical perspective. Rev. Endocr. Metab. Disord. 21(4), 527–536 (2020). https://doi.org/10.1007/s11154-020-09564-7
doi: 10.1007/s11154-020-09564-7
pubmed: 32488741
M.V. Davi, L. Dalle Carbonare, A. Giustina, M. Ferrari, A. Frigo, V. Lo Cascio, G. Francia, Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease. Eur. J. Endocrinol. 159(5), 533–540 (2008). https://doi.org/10.1530/EJE-08-0442
doi: 10.1530/EJE-08-0442
pubmed: 18765561
A. Giustina, Acromegaly and vertebral fractures: facts and questions. Trends Endocrinol. Metab. 31(4), 274–275 (2020). https://doi.org/10.1016/j.tem.2020.01.011
doi: 10.1016/j.tem.2020.01.011
pubmed: 32187523
L. Di Filippo, A.M. Formenti, M. Doga, E. Pedone, P. Rovere-Querini, A. Giustina, Radiological thoracic vertebral fractures are highly prevalent in COVID-19 and predict disease outcomes. J. Clin. Endocrinol. Metab. dgaa738 (2020). https://doi.org/10.1210/clinem/dgaa738 . [Epub ahead of print]. PMID: 33159451
A. Giustina, P. Chanson, D. Kleinberg, M.D. Bronstein, D.R. Clemmons, A. Klibanski, A.J. van der Lely, C.J. Strasburger, S.W. Lamberts, K.K. Ho, F.F. Casanueva, S. Melmed, G. Acromegaly Consensus, Expert consensus document: a consensus on the medical treatment of acromegaly. Nat. Rev. Endocrinol. 10(4), 243–248 (2014). https://doi.org/10.1038/nrendo.2014.21
doi: 10.1038/nrendo.2014.21
pubmed: 24566817
A. Giustina, M.D. Bronstein, F.F. Casanueva, P. Chanson, E. Ghigo, K.K. Ho, A. Klibanski, S. Lamberts, P. Trainer, S. Melmed, Current management practices for acromegaly: an international survey. Pituitary 14(2), 125–133 (2011). https://doi.org/10.1007/s11102-010-0269-9
doi: 10.1007/s11102-010-0269-9
pubmed: 21063787
G. Mazziotti, A. Giustina, Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review. Pituitary 13(1), 60–67 (2010). https://doi.org/10.1007/s11102-009-0169-z
doi: 10.1007/s11102-009-0169-z
pubmed: 19189218
A. Giustina, G. Mazziotti, V. Torri, M. Spinello, I. Floriani, S. Melmed, Meta-analysis on the effects of octreotide on tumor mass in acromegaly. PLoS One 7(5), e36411 (2012). https://doi.org/10.1371/journal.pone.0036411
doi: 10.1371/journal.pone.0036411
pubmed: 22574156
pmcid: 3344864
A. Giustina, A. Barkan, F.F. Casanueva, F. Cavagnini, L. Frohman, K. Ho, J. Veldhuis, J. Wass, K. Von Werder, S. Melmed, Criteria for cure of acromegaly: a consensus statement. J. Clin. Endocrinol. Metab. 85(2), 526–529 (2000). https://doi.org/10.1210/jcem.85.2.6363
doi: 10.1210/jcem.85.2.6363
pubmed: 10690849
A. Giustina, P. Chanson, M.D. Bronstein, A. Klibanski, S. Lamberts, F.F. Casanueva, P. Trainer, E. Ghigo, K. Ho, S. Melmed, G. Acromegaly Consensus, A consensus on criteria for cure of acromegaly. J. Clin. Endocrinol. Metab. 95(7), 3141–3148 (2010). https://doi.org/10.1210/jc.2009-2670
doi: 10.1210/jc.2009-2670
pubmed: 20410227
A. Giustina, S. Bonadonna, G. Bugari, A. Colao, R. Cozzi, S. Cannavo, L. de Marinis, E. Degli Uberti, F. Bogazzi, G. Mazziotti, F. Minuto, M. Montini, E. Ghigo, High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. Eur. J. Endocrinol. 161(2), 331–338 (2009). https://doi.org/10.1530/EJE-09-0372
doi: 10.1530/EJE-09-0372
pubmed: 19465485
A. Giustina, G. Mazziotti, S. Cannavo, R. Castello, G. Arnaldi, G. Bugari, R. Cozzi, D. Ferone, A.M. Formenti, E. Gatti, S. Grottoli, P. Maffei, F. Maffezzoni, M. Montini, M. Terzolo, E. Ghigo, High-dose and high-frequency lanreotide autogel in acromegaly: a randomized, multicenter study. J. Clin. Endocrinol. Metab. 102(7), 2454–2464 (2017). https://doi.org/10.1210/jc.2017-00142
doi: 10.1210/jc.2017-00142
pubmed: 28419317
M.R. Gadelha, M.D. Bronstein, T. Brue, M. Coculescu, M. Fleseriu, M. Guitelman, V. Pronin, G. Raverot, I. Shimon, K.K. Lievre, J. Fleck, M. Aout, A.M. Pedroncelli, A. Colao, C.S.G. Pasireotide, Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2(11), 875–884 (2014). https://doi.org/10.1016/S2213-8587(14)70169-X
doi: 10.1016/S2213-8587(14)70169-X
pubmed: 25260838
A. Giustina, G. Arnaldi, F. Bogazzi, S. Cannavo, A. Colao, L. De Marinis, E. De Menis, E. Degli Uberti, F. Giorgino, S. Grottoli, A.G. Lania, P. Maffei, R. Pivonello, E. Ghigo, Pegvisomant in acromegaly: an update. J. Endocrinol. Invest. 40(6), 577–589 (2017). https://doi.org/10.1007/s40618-017-0614-1
doi: 10.1007/s40618-017-0614-1
pubmed: 28176221
pmcid: 5443862
G. Mazziotti, I. Floriani, S. Bonadonna, V. Torri, P. Chanson, A. Giustina, Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. J. Clin. Endocrinol. Metab. 94(5), 1500–1508 (2009). https://doi.org/10.1210/jc.2008-2332
doi: 10.1210/jc.2008-2332
pubmed: 19208728
G. Mazziotti, T. Porcelli, F. Bogazzi, G. Bugari, S. Cannavo, A. Colao, R. Cozzi, L. De Marinis, E. degli Uberti, S. Grottoli, F. Minuto, M. Montini, M. Spinello, A. Giustina, Effects of high-dose octreotide LAR on glucose metabolism in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy. Eur. J. Endocrinol. 164(3), 341–347 (2011). https://doi.org/10.1530/EJE-10-0811
doi: 10.1530/EJE-10-0811
pubmed: 21212103
S. Frara, F. Maffezzoni, G. Mazziotti, A. Giustina, Current and emerging aspects of diabetes mellitus in acromegaly. Trends Endocrinol. Metab. 27(7), 470–483 (2016). https://doi.org/10.1016/j.tem.2016.04.014
doi: 10.1016/j.tem.2016.04.014
pubmed: 27229934
Smith, S. M., Boppana, A., Traupman, J. A., Unson, E., Maddock, D. A., Chao, K., Dobesh, D. P., Brufsky, A., Connor, R. I. Impaired glucose metabolism in patients with diabetes, prediabetes, and obesity is associated with severe COVID-19. J. Med. Virol. (2020). https://doi.org/10.1002/jmv.26227
R. Salvatori, L.B. Nachtigall, D.M. Cook, V. Bonert, M.E. Molitch, S. Blethen, S. Chang, S.S. Group, Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naive patients with acromegaly. Pituitary 13(2), 115–122 (2010). https://doi.org/10.1007/s11102-009-0207-x
doi: 10.1007/s11102-009-0207-x
pubmed: 19898989
R. Salvatori, W.W. Woodmansee, M. Molitch, M.B. Gordon, K.G. Lomax, Lanreotide extended-release aqueous-gel formulation, injected by patient, partner or healthcare provider in patients with acromegaly in the United States: 1-year data from the SODA registry. Pituitary 17(1), 13–21 (2014). https://doi.org/10.1007/s11102-012-0460-2
doi: 10.1007/s11102-012-0460-2
pubmed: 23314980
S. Melmed, V. Popovic, M. Bidlingmaier, M. Mercado, A.J. van der Lely, N. Biermasz, M. Bolanowski, M. Coculescu, J. Schopohl, K. Racz, B. Glaser, M. Goth, Y. Greenman, P. Trainer, E. Mezosi, I. Shimon, A. Giustina, M. Korbonits, M.D. Bronstein, D. Kleinberg, S. Teichman, I. Gliko-Kabir, R. Mamluk, A. Haviv, C. Strasburger, Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial. J. Clin. Endocrinol. Metab. 100(4), 1699–1708 (2015). https://doi.org/10.1210/jc.2014-4113
doi: 10.1210/jc.2014-4113
pubmed: 25664604
Samson, S. L., Nachtigall, L. B., Fleseriu, M., Gordon, M. B., Bolanowski, M., Labadzhyan, A., Ur, E., Molitch, M., Ludlam, W. H., Patou, G., Haviv, A., Biermasz, N., Giustina, A., Trainer, P. J., Strasburger, C. J., Kennedy, L., Melmed, S. Maintenance of acromegaly control in patients switching from injectable somatostatin receptor ligands to oral octreotide. J. Clin. Endocrinol. Metab. 105(10) (2020). https://doi.org/10.1210/clinem/dgaa526
F. Maffezzoni, S. Frara, M. Doga, G. Mazziotti, A. Giustina, New medical therapies of acromegaly. Growth Horm. IGF Res. 30-31, 58–63 (2016). https://doi.org/10.1016/j.ghir.2016.10.001
doi: 10.1016/j.ghir.2016.10.001
pubmed: 27745780
A. Giustina, M.D. Bronstein, P. Chanson, S. Petersenn, F.F. Casanueva, C. Sert, A. Houchard, S. Melmed, Staging and managing patients with acromegaly in clinical practice: baseline data from the SAGIT(R) validation study. Pituitary 22(5), 476–487 (2019). https://doi.org/10.1007/s11102-019-00977-5
doi: 10.1007/s11102-019-00977-5
pubmed: 31338660
pmcid: 6728296